81 related articles for article (PubMed ID: 26859934)
1. [SILODOSIN IN THE TREATMENT OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA--RESULTS OF RUSSIAN MULTICENTER OBSERVATIONAL STUDY].
Pushkar DY; Bernikov AN; Sadchenko AV
Urologiia; 2015; (5):31-4, 36-7. PubMed ID: 26859934
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of 8-mg once-daily vs 4-mg twice-daily silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (SILVER Study): a 12-week, double-blind, randomized, parallel, multicenter study.
Choo MS; Song M; Kim JH; Lee KS; Kim JC; Kim SW; Yang SK; Lee JG; Lee JZ; Kim DK; Park WH; Kim KD; Na YG; Kwon DD; Paick JS
Urology; 2014 Apr; 83(4):875-81. PubMed ID: 24529580
[TBL] [Abstract][Full Text] [Related]
3. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
Yu HJ; Lin AT; Yang SS; Tsui KH; Wu HC; Cheng CL; Cheng HL; Wu TT; Chiang PH
BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Silodosin versus Tadalafil in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.
Yoshida M; Origasa H; Seki N
Low Urin Tract Symptoms; 2017 Sep; 9(3):176-186. PubMed ID: 28439987
[TBL] [Abstract][Full Text] [Related]
5. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
7. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
Novara G; Chapple CR; Montorsi F
BJU Int; 2014 Sep; 114(3):427-33. PubMed ID: 24571313
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Efficacy and Safety of Silodosin on Nocturia in Patients With Benign Prostatic Hyperplasia: A Multicenter, Prospective, Open-label, Single-arm, Phase IV Trial.
Cho KJ; Lee JZ; Song YS; Choi JB; Kim DK; Kim YT; Kim JC
Urology; 2018 Nov; 121():153-157. PubMed ID: 30098325
[TBL] [Abstract][Full Text] [Related]
9. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
Kawabe K; Yoshida M; Homma Y;
BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
[TBL] [Abstract][Full Text] [Related]
10. [Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality].
Kogan MI; Kireev AIu
Urologiia; 2013; (6):58-60. PubMed ID: 24649766
[TBL] [Abstract][Full Text] [Related]
11. Effects of silodosin on sexual function - realistic picture from the everyday clinical practice.
Capogrosso P; Serino A; Ventimiglia E; Boeri L; Dehò F; Damiano R; Briganti A; Montorsi F; Salonia A
Andrology; 2015 Nov; 3(6):1076-81. PubMed ID: 26446512
[TBL] [Abstract][Full Text] [Related]
12. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
Capitanio U; Salonia A; Briganti A; Montorsi F
Int J Clin Pract; 2013 Jun; 67(6):544-51. PubMed ID: 23409749
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of adverse events and the continuance rate of silodosin in all patients who received silodosin for lower urinary tract symptoms suggestive of benign prostatic hyperplasia].
Furuya R; Masumori N; Furuya S; Ogura H; Mutoh M; Kobayashi K; Hisasue S; Tsukamoto T
Nihon Hinyokika Gakkai Zasshi; 2010 Jan; 101(1):13-7. PubMed ID: 20158073
[TBL] [Abstract][Full Text] [Related]
14. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia.
Homma Y; Kawabe K; Takeda M; Yoshida M
Urology; 2010 Dec; 76(6):1446-50. PubMed ID: 20472263
[TBL] [Abstract][Full Text] [Related]
15. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S; Benzeroual KE
Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
[TBL] [Abstract][Full Text] [Related]
16. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
Novara G; Chapple CR; Montorsi F
BJU Int; 2015 May; 115(5):802-14. PubMed ID: 25130493
[TBL] [Abstract][Full Text] [Related]
17. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
18. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
19. [Optimum initial dose of silodosin for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia].
Wada N; Numata A; Yamaguchi S; Osanai H; Mori T; Hou K; Fujisawa M; Kaneko S; Kakizaki H
Hinyokika Kiyo; 2011 Jun; 57(6):297-302. PubMed ID: 21795831
[TBL] [Abstract][Full Text] [Related]
20. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
